Cosentyx (secukinumab) is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug known as a monoclonal antibody, which works by targeting and blocking a specific protein in the body (interleukin-17A) that plays a key role in inflammation [1].

Regarding the question of how Cosentyx affects general vaccine effectiveness, there is limited information available specifically on this topic. However, it is known that medications like Cosentyx, which target the immune system, can potentially affect the body's ability to respond to vaccines [2]. According to the Centers for Disease Control and Prevention (CDC), "live vaccines generally should not be given for 3 weeks before starting immunosuppressive drugs or for the duration of therapy and for 3 months after discontinuing immunosuppressive drugs" [3].

Cosentyx is not a live vaccine, but it is an immunosuppressive drug. Therefore, it is important to consult with a healthcare provider before receiving any vaccinations while taking Cosentyx [2]. The manufacturer of Cosentyx, Novartis, states that "the immune response to non-live vaccines may be reduced" in patients taking Cosentyx [1]. However, the impact of Cosentyx on the effectiveness of vaccines is not well understood and more research is needed in this area [2].

In summary, Cosentyx can potentially affect the body's ability to respond to vaccines, but the specific impact on general vaccine effectiveness is not well understood. It is important to consult with a healthcare provider before receiving any vaccinations while taking Cosentyx.

Sources:

1. Cosentyx (secukinumab) [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2021. Available from: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
2. Cosentyx (secukinumab) [Patient Information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2021. Available from: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx-pm-tri.pdf>.
3. Centers for Disease Control and Prevention. Vaccination of persons with altered immunocompetence. In: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013;62(No. RR-4):1-28. Available from: <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm>.
4. DrugPatentWatch. Secukinumab. Available from: <https://www.drugpatentwatch.com/drugs/secukinumab>.